An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Incyte (Nasdaq:INCY) has scheduled its Q4 & YE 2023 financial results conference call and webcast for February 13, 2024. The press release will be at 7:00 a.m. ET, followed by the conference call at 8:00 a.m. ET. The company will provide a domestic and international dial-in number, along with a conference ID number for participation. A replay of the conference call will be available for thirty days, and the webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
Positive
None.
Negative
None.
WILMINGTON, Del.--(BUSINESS WIRE)--
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2023 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 13, 2024.
The schedule for the press release and conference call/webcast is as follows:
Q4 & YE 2023 Press Release: February 13, 2024 at 7:00 a.m. ET
Q4 & YE 2023 Conference Call: February 13, 2024 at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13744020
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13744020.
The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.
